Indeed, the EGFR inhibitor cetuximab in combination with radiation enhanced locoregional control and prolonged patient survival in locoregionally advanced HNSCC and has been FDA‐approved for this patient population [12]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.